Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trialVolker Kunzmann, Wolfgang Blau, Jens T. Siveke et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 202
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective <scp>QOLIXANE</scp> trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registrySalah‐Eddin Al‐Batran, Ursula Vehling‐Kaiser, Ralf‐Dieter Hofheinz et al.|International Journal of Cancer|2020Cited by 21
P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)Katja Sockel, Uwe Platzbecker, Johannes Schetelig et al.|HemaSphere|2023Cited by 0
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 <scp>DELTA</scp> TrialKatja Sockel, Uwe Platzbecker, Christoph Röllig et al.|American Journal of Hematology|2025Cited by 0